Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The double-blind phase III SINGLE study compared dolutegravir plus abacavir/lamivudine (n = 411) to efavirenz/emtricitabine/tenofovir (n = 419) in treatment-naive patients[Walmsley 2013]
- The dolutegravir regimen was superior to the efavirenz regimen at the Week 48 primary efficacy analysis with 88% vs 81%, respectively, achieving HIV-1 RNA < 50 copies/mL[Walmsley 2013]
- Superior efficacy of the dolutegravir regimen was maintained at the Week 144 analysis with 71% vs 63%, respectively, achieving HIV-1 RNA < 50 copies/mL[Walmsley 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy